CTOs on the Move

Genalyte

www.genalyte.com

 
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.genalyte.com
  • 10520 Wateridge Cir
    San Diego, CA USA 92121
  • Phone: 858.956.1200

Executives

Name Title Contact Details

Funding

Genalyte raised $44M on 08/18/2015
Genalyte raised $36M on 11/19/2016
Genalyte raised $50M on 01/11/2021

Similar Companies

NEO U

NEO U is a live streaming and on demand platform for trainers and brands to scale to a world-wide audience. We host top fitness experts and workout concepts from around the world in our state-of-the-art fitness hub in Midtown Manhattan.

Wellnet Healthcare

Wellnet Healthcare is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic

Welly

First aid for when fun wins.

Mills-Peninsula Health Services

Mills-Peninsula Health Services is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.